November 4, 2025
WHEREAS, the Pharmaceutical Industry Labor-Management Association (PILMA) is a coalition of labor unions and companies in the pharmaceutical industry united to grow the economy, create high-quality union jobs, and foster medical innovation; and
WHEREAS, PILMA’s mission includes supporting policies that strengthen American infrastructure, and ensure the timely construction of projects that sustain union careers in skilled trades; and
WHEREAS, the biopharmaceutical industry has announced nearly $500 billion in new investments across the United States, driving innovation, domestic manufacturing, and the creation of good-paying union jobs; and
WHEREAS, these projects, spanning research, production, and infrastructure, are essential to maintaining America’s leadership in life sciences and to delivering lifesaving medicines for patients; and
WHEREAS, long and unpredictable federal permitting timelines have delayed or discouraged critical infrastructure, affordable energy and manufacturing projects that could otherwise strengthen domestic supply chains, support job growth, and enhance national competitiveness; and
WHEREAS, uncertainty in permitting processes creates inefficiencies, increases costs, and limits the ability of labor and industry to plan and execute projects that benefit communities across the nation; and
WHEREAS, responsible permitting reform can accelerate project delivery by promoting coordination among federal agencies, establishing clear and enforceable timelines, and improving transparency without compromising environmental, safety, or labor standards; and
BE IT RESOLVED, that the trade union and company trustees of PILMA support balanced federal permitting reform that streamlines approvals for infrastructure and manufacturing projects, enhances interagency coordination, and provides greater predictability for project sponsors and workers; and
BE IT FURTHER RESOLVED, that PILMA urges federal agencies to modernize and strengthen the permitting process by:
- Establishing clear deadlines and accountability for agency reviews;
- Enhancing transparency and public access to project status and review timelines;
- Improving coordination among federal, state, and local agencies; and
- Ensuring that reforms uphold environmental protections, worker safety, and opportunities for union labor participation; and
BE IT FURTHER RESOLVED, that PILMA will advocate for responsible permitting policies that advance timely, efficient, and equitable development of projects supporting biopharmaceutical innovation, and infrastructure modernization—creating union jobs and reinforcing America’s leadership in innovation.
Citations:
1. We Work for Health. “U.S. Biopharma Investment Watch.” 2025.